Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing

International Immunology

Volumn 9, Issue 8, 1997, Pages 1085-1093

  Smith, M Charles ^a,d   Pendleton, C David ^a   Maher, V Ellen ^a   Kelley, Michael J ^b   Carbone, David P ^c   Berzofsky, Jay A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Class I MHC binding; Epitopes; Oncogene; Proteolysis

Indexed keywords

1,10 PHENANTHROLINE; CANCER VACCINE; EPITOPE; HLA A2 ANTIGEN; PROTEINASE INHIBITOR; RAS PROTEIN; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ARTICLE; CODON; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE MUTATION; HUMAN; HUMAN CELL; ONCOGENE; ONCOGENE RAS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; T LYMPHOCYTE; TUMOR IMMUNITY;

ANTIGEN PRESENTATION; BINDING SITES; CANCER VACCINES; CELL CULTURE TECHNIQUES; EPITOPES; HLA-A2 ANTIGEN; HUMANS; PEPTIDES; POINT MUTATION; RAS PROTEINS;

EID: 0030872308     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/9.8.1085     Document Type: Article

References (57)

1. Townsend, A. and Bodmer, H. 1989. Antigen recognition by class I-restricted T lymphocytes. Annu. Rev. Immunol. 7:601.
2. Germain, R. N. and Margulies, D. H. 1993. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11:403.
3. Yewdell, J. W. and Hackett, C. J. 1987. The specificity and function of T lymphocytes induced by influenza A viruses. In Krug, R., ed. The Influenza Viruses. Plenum Press, New York.
4. Takahashi, H., Merli, S., Putney, S. D., Houghten, R., Moss, B., Germain, R. N. and Berzofsky, J. A. 1989. A single amino acid interchange yields reciprocal CTL specificities for HIV gp160. Science 246:118.
5. Takahashi, H., Nakagawa, Y., Pendleton, C, D., Houghten, R. A., Yokomuro, K., Germain, R. N. and Berzofsky, J. A. 1992. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science 255:333.
6. Sidransky, D., Tokino, T., Hamilton, S. R., Kinzler, K. W., Levin, B., Frost, P. and Vogelstein, B. 1992. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102.
7. Stauss, H. J. 1996. Mutant Ras proteins and peptides: bad news for tumors. J. Natl. Cancer Inst. 87:1820.
8. Bos, J. L. 1989. ras oncogenes in human cancer: a review. Cancer Res. 49:4682.
9. Peace, D. J., Chen, W., Nelson, H. and Cheever, M. A. 1991. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J. Immunol. 146:2059.
10. Jung, S. and Schluesener, H. J. 1991. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J. Exp. Med. 173:273.
11. Fenton, R. G., Taub, D. D., Kwak, L. W., Smith, M. R. and Longo, D. L. 1993. Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J. Natl Cancer Inst. 85:1294.
12. Fossum, B., Gedde-Dahl, T, III, Hansen, T., Eriksen, J. A., Thorsby, E. and Gaudernack, G. 1993. Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells. Eur. J. Immunol. 23:2687.
13. Gedde-Dahl, T., III, Spurkland, A., Fossum, B., Wittinghofer, A., Thorsby, E. and Gaudernack, G. 1994. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA. Eur J. Immunol. 24:410.
14. + T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res. 55:2984.
15. Gjertsen, M. K., Bakka, A., Breivik, J., Saeterdal, I., Solheim, B. G., Søreide, O., Thorsby, E. and Gaudernack, G. 1995. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 346:1399.
16. Peace, D J., Smith, J. W., Chen, W., You, S.-G., Cosand, W. L., Blake, J. and Cheever, M. A. 1994. Lysis of Ras oncogenetransformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated Ras peptide. J. Exp. Med. 179:473.
17. Gjertsen, M. K., Bakka, A., Breivik, J., Saeterdal, I., Gedde-Dahl, T., III, Stokke, K. T., Solheim, B. G., Egge, T. S., Søreide, O., Thorsby, E. and Gaudernack, G. 1996. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int. J. Cancer 65:450.
18. Skipper, J. and Stauss, H. J. 1993, Identification of two cytotoxic T lymphocyte-recognized epitopes in the ras protein. J. Exp. Med. 177:1493.
19. Fenton, R. G., Keller, C. J., Hanna, N. and Taub, D. D. 1995. Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli. J. Natl Cancer Inst. 87:1853.
20. + T cells recognize a peptide corresponding to a common mutation (13Gly → Asp). Int. J. Cancer 56:40.
21. Carbone, D. P., Ciernik, I. F., Yanuck, M., Smith, M. C., Kelley, M., Johnson, B. E., Allegra, C., Pendleton, C. D., Khleif, S., Kaye, F., Steinberg, S., Gazdar, A. F., Minna, J. D. and Berzofsky, J. A. 1994, Mutant p53 and ras proteins as immunotherapeutic targets. Ann. Oncol. 5:117.
22. Knapp, W., Dörken, B., Gilks, W. R., Rieber, E. P., Schmidt, R. E., Stein. H. and von dem Borne, A. E. G. Kr. 1989. Leucocyte Typing IV: White Cell Differentiation Antigens. Oxford University Press, Oxford.
23. Salter, R. D., Howell, D. N. and Cresswell, P. 1985. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids, Immunogenetics 21:235.
24. Spies, T. and DeMars, R. 1991. Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature 351:323.
25. Stewart, J. M. and Young, J. D. 1984. Solid Phase Peptide Synthesis, 2nd edn. Pierce Chemical Company, Rockford, IL.
26. Gotch, F. M., Rothbard, J., Howland, K., Townsend, A. R. M. and McMichael, A. J. 1987. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 326:881.
27. Nijman, H. W., Houbiers, J. G. A., Vierboom, M. P. M., van der Burg, S. H., Drijfhout, J. W., D'Amaro, J., Kenemans, P., Melief, C. J. M. and Kast, W. M. 1993. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23:1215.
28. Takahashi, H., Cease, K. B. and Berzofsky, J. A. 1989. Identification of proteases that process distinct epitopes on the same protein. J. Immunol. 142:2221.
29. Parham, P. and Brodsky, F. M. 1981. Partial purification and some properties of BB7.2: a cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol. 3:277.
30. McMichael, A. J., Parham, P., Rust, N. and Brodsky, F. 1980. A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17, Hum. Immunol 1:121.
31. Widmann, C., Maryanski, J. L., Romero, P. and Corradin, G. 1991. Differential stability of antigenic MHC class I-restricted synthetic peptides. J. Immunol. 147:3745.
32. Sherman, L. A., Burke, T. A. and Biggs, J. A. 1992. Extracellular processing of peptide antigens that bind class I major histocompatibility molecules. J. Exp. Med. 175:1221.
33. Kozlowski, S., Corr, M., Takeshita, T., Boyd, L. F., Pendleton, C. D., Germain, R. N., Berzofsky, J. A. and Margulies, D. H. 1992. Serum angiotensin-1 converting enzyme activity processes an HIV 1 gp160 peptide for presentation by MHC class I molecules. J. Exp. Med. 175:1417.
34. Kozlowski, S., Corr, M., Shirai, M., Boyd, L. F., Pendleton, C, D., Berzofsky, J. A. and Margulies, D. H. 1993 Multiple pathways are involved in the extracellular processing of major histocompatibility complex class I-restricted peptides. J. Immunol. 151:4033.
35. Rammensee, H.-G., Friede, T. and Stevanovíc, S. 1995. MHC ligands and peptide motifs: first listing, Immunogenetics 41:178.
36. Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E. and Engelhard, V. H. 1992. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255:1261.
37. Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M. and Sette, A. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929.
38. Alexander-Miller, M, A., Parker, K. C., Tsukui, T., Pendleton, C. D., Coligan, J. E. and Berzofsky, J. A. 1996. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-1 envelope protein to human CTL. Int. Immunol. 8:641.
39. + CTL by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol. 5:849.
40. Gabrilovich, D. I., Nadaf, S., Corak, J., Berzofsky, J. A. and Carbone, D. P. 1996. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell. Immunol. 170:111.
41. Gabrilovich, D. I., Ciernik, I. F. and Carbone, D. P. 1996. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol. 170:101.
42. + helper T cells, J. Exp. Med. 171:1315.
43. + T cells. J. Clin. Invest. 94:797.
44. Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T. and Falo, L. D., Jr. 1996. Peptide-pulsed dendritic cells induce antigenspecific, CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
45. Zitvogel, L., Mayordomo, J. I., Tjandrawan, I., DeLeo, A. B., Clarke, M. R., Lotze, M. T. and Storkus, W. J. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
46. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., DeLeo, A. B. and Lotze, M T. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Medicine 1:1297.
47. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., De Cesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E. and DeLeo, A. B. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med 183:1357.
48. Paglia, P., Chiodoni, C., Rodolfo, M. and Colombo, M. P. 1996. Murine dendritic cells loaded in vitro vitro soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317.
49. Young, J. W. and Inaba, K. 1996. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183:7.
50. Meister, G. E., Roberts, C. G. P., Berzofsky, J. A. and DeGroot, A. S. 1995. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine 13:581.
51. Parker, K. C., Bednarek, M. A., Hull, L K., Utz, U., Cunningham, B., Zweerink, H. J., Biddison, W. E. and Coligan, J, E. 1992. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J. Immunol. 149:3580.
52. Berzofsky, J. A., Pendleton, C, D., Clerici, M., Ahlers, J., Lucey, D. R., Putney, S. D. and Shearer, G. M. 1991. Construction of peptides encompassing multideterminant clusters of HIV envelope to induce in vitro T-cell responses in mice and humans of multiple MHC types. J. Clin. Invest. 88:876.
53. Clerici, M., Lucey, D. R., Zajac, R. A., Boswell, R. N., Gebel, H. M., Takahashi, H., Berzofsky, J. and Shearer, G. M. 1991. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J. Immunol. 146:2214.
54. Berzofsky, J. A. 1993. Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and cross-reactivity of engineered vaccines. Ann. NY Acad. Sci. 690:256.
55. Berzofsky, J. A. 1995. Designing peptide vaccines to broaden recognition and enhance potency. Ann. NY Acad. Sci. 754:161.
56. Berzofsky, J. A. and Berkower, I. J. 1995, Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-95. AIDS 9 (Suppl. A):S143.
57. Schumacher, T. N. M., Heemels, M.-T., Neefjes, J. J., Kast, W. M., Melief, C. J. M. and Ploegh, H. L. 1990. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 62:563.